Biotech | August 30, 2021
Vivo Bio Tech enters long-term contract with Bio E
The value of the contract is estimated to be between Rs 20-30 crores per year for the next three years
The value of the contract is estimated to be between Rs 20-30 crores per year for the next three years
The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services
The aim is to give a fillip to R&D in the health sector to face the Covid-19 challenge
Viraleze was developed for application in the nasal cavity to help reduce exposure to respiratory viruses, including SARS-CoV-2. The product is registered for sale in Europe and India, and available online in certain markets
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
Shanghai Roche Pharmaceuticals and Shanghai KeChow Pharma, entered into a cooperation agreement to improve market access of Zelboraf in China.
This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC
FDA approval of the first interchangeable biosimilar insulin will drive the US Insulin biosimilar market, says Kuick Research.
The company's discovery services support a wide range of global innovator companies from start-ups to large pharma companies, across a diverse set of therapeutic areas including oncology, CNS, antivirals, and inflammation among others
National Institute of Animal Biotechnology, Hyderabad can now conduct quality checks and consequent lot release of Covid-19 vaccines
Subscribe To Our Newsletter & Stay Updated
